Press Releases
Eir Ventures Invests in Purpose Pharma
We are very happy to announce our latest investment in Purpose Pharma. Purpose Pharma is a patient-centric European based pharmaceutical company focusing on the development and commercialization of novel rare disease and specialty care products in areas of high unmet medical need. Tobias...
Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain
Eir Ventures invests in Dania Tx
Eir Ventures celebrates 3 years anniversary
On July 10, 2020, Eir Ventures I was launched with the announcement of the first close of our fund.
Lovisa Backemar new Principal.
Eir Ventures welcomes Lovisa Backemar as Principal in the Eir Ventures Team.
Eir invests in RAPP
Eir invests in GutCRINE
Eir Ventures invests in Henlez
Eir Ventures portfolio company, Pretzel Therapeutics, announces USD 72,5M series A financing
Eir Ventures invests in Hoba Therapeutics
Eir Ventures joins oversubscribed investment round in Attgeno
Eir Ventures strengthens team – appoints three new Partners
Eir Ventures joins oversubscribed investment round in Cinclus Pharma
Eir Ventures leads €28M investment in Scenic Biotec
Eir Ventures today announced the completion of an investment in Strike Pharma
Eir Ventures today announced the completion of an investment in Strike Pharma
Eir Ventures announces Co-investment agreement with Copenhagen University
Eir Ventures is happy to welcome two interns at our Stockholm office during the Spring semester of 2022
Pok Yeung Lee and Jorge Pérez Hermilla will join the Eir Ventures Stockholm team in January 2022.
Eir Ventures expands team with new principal
Eir Ventures welcomes Tobias Horneman-Thielcke as senior Principal in the Eir Ventures Team.
Eir Ventures Closes Life Science Venture Fund at EUR122 million
Eir Ventures completes investment in ArgusEye to advance innovative sensor technology for real-time monitoring of bioproduction processes
Eir Ventures upscales with Investment Associate
Eir Ventures welcomes Gökçe Günaydın as Investment Associate.
Eir Ventures’ first “seedling” Synklino ApS completes oversubscribed DKK 106 million series A round
IO Biotech, Inc. Announces Pricing of Initial Public Offering
Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer
Eir Ventures completes investment in one-carbon Therapeutics. Magnus Persson and Alexander Mata join the board of directors, with Magnus Persson as chairman
Articles & Other News
Interview with Eir Ventures’ Magnus Persson in Dagens Industri
För 25 år sedan var han med och grundade Healthcap. Nu har Magnus Persson gjort det igen, med Eir Ventures, har han startat ett nytt bolag specialiserat på life science-investeringar. ”Sverige och Norden har länge visat sig fantastiskt när det gäller innovation”, konstaterar han. Click here to...
Interview with Eir Ventures’ Stephan Christgau in NASDAQ newsletter
Q: Eir Ventures has now been in operations for 6 months since the launch last summer, how has that been? We were delighted to be able to reach the first close of Eir Ventures last summer. Obviously raising a new first time life science venture fund is never easy, and completing the task during a...